Inclusion Criteria:
- Documented diagnosis of Myelodysplastic syndrome, Acute myeloid leukemia, Multiple
myeloma, Non-Hodgkin's lymphoma, Hodgkin's lymphoma or metastatic or inoperable solid
tumors
- Life expectancy of ≥ 3 months
- Stable renal function without dialysis for at least 2 months prior to investigational
product administration
- Has moderate or severe hepatic impairment as defined by National Cancer Institute
Organ Dysfunction Working Group criteria
Exclusion Criteria:
- Chemotherapy or radiotherapy within 4 weeks prior to the first day of investigational
product administration
- Persistent, clinically significant non-hematologic toxicities from prior therapies
which have not recovered to < Grade 2
- Any condition including the presence of laboratory abnormalities, which places the
participant at unacceptable risk if he/she were to participate in the study
- History of inflammatory bowel disease, celiac disease, prior gastrectomy, gastric
bypass, upper bowel removal, or any other gastrointestinal disorder or defect that
would interfere with the absorption of the investigational product and/or predispose
the participant to an increased risk of gastrointestinal toxicity
Other protocol-defined inclusion/exclusion criteria apply
